Does Mirtazapine Increase Liver Enzymes?
Yes, mirtazapine can cause elevation of liver enzymes, though this occurs infrequently. According to FDA labeling, clinically significant ALT elevations (≥3 times the upper limit of normal) were observed in 2% of patients treated with mirtazapine compared to 0.3% of placebo patients in controlled trials 1.
Incidence and Clinical Significance
The risk of drug-induced liver injury (DILI) with mirtazapine is relatively low compared to other antidepressants:
- In a large surveillance study of 184,234 psychiatric inpatients, mirtazapine was associated with minimal enzyme elevation patterns - notably, it "hardly increased enzyme values" for glutamat-pyruvat-transaminase (GPT/ALT) and glutamat-oxalat-transaminase (GOT/AST), though it performed worse for gamma-glutamyl-transferase (GGT) values 2
- The overall incidence of DILI with mirtazapine appears lower than with tricyclic antidepressants like clomipramine (0.23%) or mianserine (0.36%), and comparable to or slightly higher than SSRIs 2
Important Clinical Considerations
Hepatotoxicity can occur even at low doses and in asymptomatic patients. Case reports document:
- Asymptomatic transaminase elevation during low-dose therapy for insomnia 3
- Severe hepatotoxicity with prolonged jaundice requiring up to 3 months for recovery after discontinuation 4
- Mirtazapine-induced steatosis (fatty liver) presenting with painless jaundice 5
Monitoring Recommendations
The FDA label explicitly states that mirtazapine should be used with caution in patients with impaired hepatic function 1. While some patients' enzyme levels normalized despite continued treatment, others required discontinuation 1.
Key monitoring points:
- Baseline liver function tests before initiation
- Monitor for clinical signs: nausea, fatigue, loss of appetite, abdominal pain, jaundice 2
- Consider periodic monitoring in patients with pre-existing liver disease or risk factors
- Elderly patients and those with renal/hepatic impairment require dose reduction due to decreased clearance 1
Mechanism and Risk Factors
Recent research suggests mirtazapine may promote hepatic steatosis through the TLR4/MyD88/NF-κB signaling pathway, increasing inflammatory markers (IL-1β, IL-6, TNF-α) in hepatocytes 6. Risk factors for liver complications in depressed patients taking mirtazapine include:
- Older age
- Longer duration of antidepressant use
- Comorbid hyperlipidemia or type 2 diabetes 6
Clinical Pitfall
Do not assume safety based on dose or duration - hepatotoxicity has been reported after both short-term use (5 days when combined with other medications 7) and long-term use (3 years 4). The metabolic adverse effects of mirtazapine (weight gain, insulin resistance, hepatic steatosis) may compound liver injury risk, particularly in patients with metabolic syndrome 8, 6.